adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low

Portfolio progress highlights the value of commercialization support as Canadian life sciences investment falls 31 per cent in Q3 2026

Vancouver (BC), Toronto (ON), and Montreal (QC), November 17, 2026 — adMare BioInnovations today announced significant progress across its portfolio of Canadian life sciences companies, which are attracting new investors, entering the clinic and reaching key research milestones despite a challenging investment climate.

New data from the Canadian Venture Capital & Private Equity Association (CVCA) shows the scale of the challenge. Life sciences venture investment in Canada fell 31 per cent to $534 million across 72 deals in the first three quarters of 2026. That is the lowest year-to-date total since 2021 and half the five-year average of $1.07 billion.

Globally, life sciences venture capital is concentrating in larger, more de-risked deals, creating a growing funding gap for early-stage companies. CVCA’s data underscores this point.  In the third quarter, one single deal captured 86 per cent of the $239 million investment, leaving just $34 million across the remaining 16 deals. This widening gap puts promising Canadian companies at risk, threatening their ability to develop promising treatments, grow and keep jobs in Canada.

“Canada has strong science and entrepreneurial ambition to develop new treatments and compete on a global scale. What’s missing is the middle: turning those start-ups into companies investors can back,” said Matthew Carlyle, President and CEO of adMare BioInnovations. “Our portfolio shows what’s possible when promising science gets the capital, expertise and support to reach the milestones investors look for.”

Despite the declining investment landscape, adMare portfolio companies continue to advance, benefiting from the organization’s proven life sciences company creation model and partnership with the Government of Canada.

Recent milestones span the research translation journey and help bring new treatments closer to patients:

Scientific validation and company creation:

  • Ocythera – Progress toward new treatments for bone and joint diseases: Building ona multi-year research collaboration with Queen’s University, adMare launched Ocythera in January 2026 and co-invested in its seed financing alongside Investissement Québec’s Fonds Impulsion. Ocythera is developing drugs that block CYP26B1, an enzyme involved in bone and cartilage development.  Since launch it has met every milestone in its development plan, with drug candidates showing  favourable preclinical results for the potential of treating several bone diseases, including multiple osteochondromas, fibrodysplasia ossificans progressiva and osteoarthritis.

Crossing the valley of death:

  • Specific Biologics – Securing a Series A investment to bring a potential ALS treatment to clinical trials:  Building on its early investment and several years of commercial research support, adMare participated in Specific Biologics’ US$35 million Series A financing to advance the company’s lead ALS program into the clinic. New investors Hatteras Venture Partners, Genesys Capital, BDC, Seido and Deepworks joined original investors Lumira Ventures and adMare. The financing also marked the first investment by BDC’s new Life Sciences Fund.

In the clinic:

  • Epitopea: Testing a potential ovarian cancer vaccine: Epitopea has treated the first patient in its OVACT Phase 1/1b clinical trial.  The study is testing the potential benefits of its off-the-shelf therapeutic mRNA cancer vaccine candidate, for advanced ovarian cancer.
  • Kainova Therapeutics – advancing cancer treatments: adMare has been a consistent investor in Kainova since its expansion to Canada in 2022. Recent financing from Canadian and European investors will support a Phase 1/2 clinical trial, to test the company’s anti-CCR8 antibody against solid tumor cancers.
  • Find Therapeutics – preparing for Phase 2 clinical trial: Investments from CTI Life Sciences, Investissement Québec and adMare will allow the company to complete safety and manufacturing work ahead of its next Phase 2 trial. Find is focused on developing therapies aimed at treating demyelinating diseases and inflammatory autoimmune conditions, such as acute optic neuritis and chronic optic neuropathy.
  • Thryv Therapeutics  – advancing potential treatments for serious heart conditions: adMare re-invested as part of Thryv’s US$30 million+ Series B financing with new investor InClin and existing investors, Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, CTI Life Sciences and Alexandria Venture Investments. This financing will support ongoing Phase 2/3 clinical studies in long QT syndrome, which causes dangerous heart rhythms, and a Phase 2a trial to treat heart failure with reduced ejection fraction.

Bridging the gap between discovery and investability

Recent federal measures strengthen both ends of the life sciences pipeline: new research chairs on the discovery side, and new tax incentives and venture capital, including BDC’s Life Sciences Fund, on the investment side.

As the federal government considers its response to the Pharmaceutical and Life Sciences Task Force and shapes the next phase of Canada’s life sciences strategy, strengthening the bridge between research and private investment will be essential to building globally competitive Canadian companies and keeping more of the value of Canadian science in Canada.

-30-

About adMare BioInnovations

As Canada’s life sciences company creation engine, adMare BioInnovations develops and helps scale a pipeline of highly investable, globally competitive life sciences companies. Through early-stage capital, scientific and drug development expertise, turnkey lab and office facilities, and focused talent and leadership development programs, adMare fills critical gaps to de-risk and accelerate innovation, create value, and anchor growth—helping to improve patient lives and achieve the vision of a national life sciences industry that leverages Canada’s scientific research excellence. The organization has helped build 54 Canadian life sciences companies that have raised $2.5B in risk capital, have a collective value of $5.8B and created more than 1000 jobs.

Media Inquiries

Bethany Moir